News Daily News Side Effects of Statins Might Be Overstated: CTT Collaboration Michael O'Riordan February 12, 2026
News Daily News Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment Yael L. Maxwell January 21, 2026
News Daily News FDA Approves Lerodalcibep for Adults With Hypercholesterolemia Yael L. Maxwell December 15, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Daily News Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients Caitlin E. Cox October 16, 2025
News Daily News ACC: It’s Time for Clinicians to Address Inflammation in CVD Caitlin E. Cox October 03, 2025
News Opinion CV Team Dispatch September 2025 Dispatch for the CV Team L.A. McKeown September 30, 2025
News Daily News Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions L.A. McKeown September 22, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025
News Conference News ESC 2025 High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors Caitlin E. Cox August 29, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Daily News Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention Michael O'Riordan May 07, 2025
News Daily News HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention Michael O'Riordan May 02, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Daily News Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD Michael O'Riordan March 06, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025